Vabysmo vs Izervay
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vabysmo | US Izervay | |
|---|---|---|
| Generic name | faricimab | avacincaptad pegol |
| Drug class | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) | Complement C5 Inhibitor |
| Treats | Wet macular degeneration, diabetic macular edema | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | Genentech (Roche) | Astellas Pharma |
| Year approved | 2022 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $85M | — |
| Common side effects | Eye inflammation, Floaters, Increased eye pressure, Blurred vision | Bleeding in the eye, Increased eye pressure, Floaters, Risk of eye infection |
Frequently asked questions
Is Vabysmo or Izervay better?
Neither is universally "better." Vabysmo (faricimab) and Izervay (avacincaptad pegol) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vabysmo and Izervay?
Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche), while Izervay is a Complement C5 Inhibitor made by Astellas Pharma. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vabysmo has the larger estimated TV advertising budget of the two.